GS-US-548-5916: A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma (NCT04854499)
GS-US-548-5916
This trial is No longer recruiting
Registration number NCT04854499
Program & service
This trial is being run with the Cancer service, and as part of the Medical Oncology program.
Trial phase
Phase 2
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Miles Andrews
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR